In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.